Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.60 |
| ▸ | DRD2 | P14416 | 4/20 | 0.60 |
| ▸ | HTR2A | P28223 | 4/20 | 0.60 |
| ▸ | HTR7 | P34969 | 4/20 | 0.60 |
| ▸ | DRD3 | P35462 | 4/20 | 0.60 |
| ▸ | HTR2B | P41595 | 4/20 | 0.60 |
| ▸ | HRH1 | P35367 | 3/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | APAF1 | O14727 | 1/20 | 0.51 |
| ▸ | HTR5A | P47898 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7147206 | 0.96 | DRD2 (0.65) | HTR1ADRD2HTR2AHTR7DRD3 | |
| SCHEMBL4476829 | 0.79 | SIGMAR1 (0.56) | HTR1ADRD2HTR2AHTR7DRD3 | |
| Hydrochloric Acid SCHEMBL4471883 | 0.78 | SIGMAR1 (0.55) | HTR1ADRD2HTR2AHTR7DRD3 | |
| SCHEMBL4477169 | 0.77 | SIGMAR1 (0.54) | HTR1ADRD2HTR2AHTR7DRD3 | |
| SCHEMBL6869743 | 0.77 | SIGMAR1 (0.62) | DRD2DRD3SIGMAR1 | |
| SCHEMBL6872612 | 0.77 | SIGMAR1 (0.72) | SIGMAR1 | |
| SCHEMBL7647981 | 0.76 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR7DRD3 | |
| SCHEMBL4473668 | 0.75 | SIGMAR1 (0.52) | SIGMAR1HTR5A | |
| SCHEMBL7146651 | 0.74 | APAF1 (0.80) | HTR1ADRD2HTR2AHTR7DRD3 | |
| SCHEMBL22528282 | 0.74 | SIGMAR1 (0.80) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140934-B1 | BENZISOXAZOLES AND PHENONES AS ALPHA-2-ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2003-10-08 | — | — | EP | disclosed |
| US-6576640-B1 | Rapidly penetration into central nervous system; treating noradrenaline deficiency; depression, Parkinson's disease | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-06-10 | — | — | US | disclosed |
| EP-1140934-A1 | BENZISOXAZOLES AND PHENONES AS $g(a) 2?-ANTAGONISTS | Janssen Pharmaceutica N.V. (BE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037466-A1 | BENZISOXAZOLES AND PHENONES AS α2-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-29 | — | — | WO | disclosed |